Vistagen to Announce FY 2024 Financial Results and Host Call on June 11, 2024

Vistagen, a biopharmaceutical company based in South San Francisco, California, and listed on NASDAQ under the ticker VTGN, is at the forefront of developing innovative therapies for psychiatric and neurological conditions. The company is set to host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results for the fiscal year ending March 31, 2024, and to provide a corporate update.

The conference call, officially titled the "Vistagen Fiscal Year 2024 Corporate Update Conference Call," will allow stakeholders and interested parties to gain insights into the company's financial performance and strategic direction. The call will be accessible via a toll-free number for U.S. participants and an international number for those calling from outside the United States. To join, U.S. participants can dial 1-877-407-9716, while international participants can dial 1-201-493-6779. The conference ID for the call is 13746589.

In addition to the live conference call, an audio webcast will be available through a provided link. Participants are encouraged to join the webcast site at least 10 minutes before the scheduled start time to ensure they don't miss any important information. For those unable to attend the live event, a playback option will be available after 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time) on the same day. The replay can be accessed by dialing 1-844-512-2921 within the U.S. or 1-412-317-6671 internationally, using the replay access ID number 13746589.

Vistagen's pioneering work in neuroscience focuses on developing novel treatments that address various psychiatric and neurological disorders. The company's pipeline includes five clinical-stage candidates known as pherines. These investigational neuroactive nasal sprays are designed with unique mechanisms that activate chemosensory neurons in the nasal passages to influence neural circuits in the olfactory system and the brain without requiring systemic absorption or receptor binding within the brain. This innovative approach holds promise for treating conditions like anxiety and depression more effectively.

In addition to the pherine-based therapies, Vistagen is also working on a sixth investigational candidate, an oral prodrug with the potential to modulate NMDA receptor activity. This candidate could offer a new avenue for managing neurological disorders, further expanding the company's portfolio of groundbreaking treatments.

Vistagen's commitment to advancing neuroscience is driven by a passion for improving the standard of care for individuals living with psychiatric and neurological conditions. The company's differentiated treatments aim to provide better outcomes and enhance the quality of life for patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!